Bone Fractures Down With GLP-1 Drugs in the PictureBone Fractures Down With GLP-1 Drugs in the Picture
(MedPage Today) — Beyond their established cardiometabolic benefits, GLP-1 receptor agonists also may be tied to improved bone health, based on an observational report. Adults with type 2 diabetes on GLP-1 agonists tended to have small but significant… (MedPage Today) — Beyond their established cardiometabolic benefits, GLP-1 receptor agonists also may be tied to Read More
GLP-1 medications show little effect on cancer, study showsGLP-1 medications show little effect on cancer, study shows
A new study suggests popular GLP-1 drugs, like Ozempic and Zepbound, may not lower cancer risk as some had hoped. A new study suggests popular GLP-1 drugs, like Ozempic and Zepbound, may not lower cancer risk as some had hoped.
The potential of GLP-1 drugs to transform medicine exploded in 2025The potential of GLP-1 drugs to transform medicine exploded in 2025
We knew that GLP-1 drugs like Ozempic and Wegovy did more than just help control type 2 diabetes and aid weight loss, but the extent of that potential really came to light in 2025 We knew that GLP-1 drugs like Ozempic and Wegovy did more than just help control type 2 diabetes and aid weight Read More
A multimodal AI model may improve recurrence risk stratification in early breast cancerA multimodal AI model may improve recurrence risk stratification in early breast cancer
An artificial intelligence (AI) model created by integrating clinical, molecular, and histopathological data significantly improved recurrence risk stratification in hormone receptor (HR)-positive, HER2-negative breast cancer, according to results presented at the San Antonio Breast Cancer Symposium (SABCS), held December 9–12, 2025.
Phase I Vaccine Trial Shows Promise for Preventing Triple-Negative Breast CancerPhase I Vaccine Trial Shows Promise for Preventing Triple-Negative Breast Cancer
(MedPage Today) — At the San Antonio Breast Cancer Symposium (SABCS), investigators reported final phase I results of an alpha-lactalbumin (aLA) vaccine designed to help prevent triple-negative breast cancer (TNBC), particularly among women at…
AI Model Improves Prediction of Early and Late Breast Cancer RecurrenceAI Model Improves Prediction of Early and Late Breast Cancer Recurrence
(MedPage Today) — At the San Antonio Breast Cancer Symposium, researchers presented a study on a multimodal artificial intelligence model that integrated clinical data, pathology-based imaging, and expanded molecular profiling to improve prediction…
Sperm donor with rare cancer-causing mutation fathers nearly 200 children across EuropeSperm donor with rare cancer-causing mutation fathers nearly 200 children across Europe
A sperm donor who carried a cancer-causing gene mutation fathered nearly 200 children, an investigation by 14 European news organizations show.
Real-World Outcomes Favor Standard Care in HER2-Positive Metastatic Breast CancerReal-World Outcomes Favor Standard Care in HER2-Positive Metastatic Breast Cancer
(MedPage Today) — At the San Antonio Breast Cancer Symposium (SABCS), a large retrospective analysis of U.S. electronic health records compared outcomes for patients with HER2-positive metastatic breast cancer who received first-line guideline…
Novel endocrine therapy improves disease-free survival over standard of care for patients with early-stage breast cancerNovel endocrine therapy improves disease-free survival over standard of care for patients with early-stage breast cancer
The investigational, oral selective estrogen receptor degrader (SERD) giredestrant given as an adjuvant therapy showed significant improvement in invasive disease-free survival (iDFS) compared with the current standard-of-care endocrine therapy in patients with early-stage, hormone receptor (HR)-positive, HER2-negative breast cancer, according to the results of a Phase III IidERA trial presented at the San Antonio Breast Cancer Symposium (SABCS), held December 9–12, 2025.
Sacituzumab govitecan-hziy led to similar progression-free survival as standard of care for some breast cancers: TrialSacituzumab govitecan-hziy led to similar progression-free survival as standard of care for some breast cancers: Trial
Patients with hormone receptor (HR)-positive, HER2-negative advanced breast cancers had similar progression-free survival (PFS) whether they were treated with sacituzumab govitecan-hziy (Trodelvy) or standard-of-care chemotherapy as the first treatment after endocrine therapy, according to results from a Phase III ASCENT-07 clinical trial presented at the San Antonio Breast Cancer Symposium (SABCS), held December 9–12, 2025.